表紙
市場調查報告書

放射性醫藥品的全球市場 - 產業考察,趨勢,預測,市場機會分析 2016年∼2024年

Radiopharmaceuticals Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

出版商 Coherent Market Insights 商品編碼 865082
出版日期 內容資訊 英文 279 Pages
商品交期: 2-3個工作天內
價格
Back to Top
放射性醫藥品的全球市場 - 產業考察,趨勢,預測,市場機會分析 2016年∼2024年 Radiopharmaceuticals Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024
出版日期: 2019年05月10日內容資訊: 英文 279 Pages
簡介

全球放射性醫藥品市場,由於以Lutathera為首的放射性核種的新核准,及放射性醫藥品的用途擴大,單株抗體的放射性標識,癌症和阿茲海默症等的早期診斷的必要性高漲等,而預計促進成長。

本報告提供全球放射性醫藥品市場調查,市場概要,各產品類型、用途、終端用戶、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查目的與前提條件

  • 調查目的
  • 假設
  • 簡稱

第2章 市場範圍

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場片段:各產品類型
    • 市場片段:各用途
    • 市場片段:各終端用戶
    • 市場片段:各地區
  • Coherent Opportunity Map(COM)

第3章 市場動態,法規,趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 法規方案
  • 償付方案
  • PEST分析
  • 波特的五力分析
  • 合作 & 夥伴關係
  • 合併、收購
  • 主要的開發趨勢
  • 流行病學

第4章 全球放射性醫藥品市場:各產品類型

  • 簡介
  • 診斷用核醫學
  • 治療用核醫學

第5章 全球放射性醫藥品市場:各用途

  • 簡介
  • 腫瘤
  • 循環系統
  • 神經
  • 內分泌
  • 其他

第6章 全球放射性醫藥品市場:各終端用戶

  • 簡介
  • 醫院
  • 專門診所
  • 診斷中心

第7章 全球放射性醫藥品市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 中南美
  • 非洲
  • 中東

第8章 競爭環境

  • 熱圖分析
  • 企業簡介
    • Progenics Pharmaceuticals, Inc.
    • NorthStar Medical Radioisotopes LLC
    • Curium Pharma
    • Life Molecular Imaging
    • Lantheus Holdings, Inc.
    • Cardinal Health, Inc.
    • General Electric Company
    • Bracco S.p.A.
    • Bayer AG
    • Advanced Accelerator Applications, S.A.
    • Eli Lilly and Company

第9章 Section

  • 參考文獻
  • 調查方法
  • 關於Coherent Market Insights
目錄

Licensing, regulations, and use of radioisotopes in the U.S. is under agencies such as the U.S. Nuclear Regulatory Commission (NRC), the U.S. Environmental Protection Agency (EPA), the U.S. Food & Drug Administration (FDA), and respective state governments. The state governments are responsible for regulating radioactive substances that occur naturally or are produced by linear accelerators and/or cyclotrons, and EPA is responsible for among other things, setting air emission and drinking water standards for radionuclides. The U.S. Food and Drug Administration (FDA) regulates manufacturing and use of linear accelerators; granting marketing authorizations to radiopharmaceutical products for diagnostic as well as therapeutic use and other activities associated with radiopharmaceutical products.

Market Dynamics

Factors such as approval of products such as Lutathera, a potential blockbuster drug (Advanced Accelerator Applications, 2018) and Axumin (2016, Blue Earth Diagnostics) has propelled global radiopharmaceuticals in nuclear medicine market growth. Newer trends such as increasing therapeutic applications of radiopharmaceuticals and radiolabeling of monoclonal antibodies are expected to support growth of the market. Subsequently, as the need for early diagnosis of diseases such as cancer and accurate diagnosis of diseases such as Alzheimer's has become more necessary (certain products have come close to this such as Amyvid and Vizamyl) radiopharmaceuticals are expected to find an even strong foothold in medical care.

Key features of the study:

  • This report provides in-depth analysis of global radiopharmaceuticals in nuclear medicine market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018-2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market

Detailed Segmentation:

  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • Tc-99m
    • In-111
    • Tl-201
    • Ga-67
    • I-123/I-125/I-131
    • Other SPECT Isotopes
    • PET Radiopharmaceuticals
    • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
    • Ru-82
    • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Ra-223
    • I-131
    • Re-186/Sm-153/Sr-90
    • Lu-177
    • Ir-192
    • Pd-103
    • Cs-131
    • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Region:
  • North America
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • U.S.
    • Canada
  • Europe
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
    • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
    • By Application:
    • Oncology
    • Cardiology
    • Neurology
    • Endocrinology
    • Others
    • By End User:
    • Hospitals
    • Specialty Clinics
    • Diagnostic Centers
    • By Country/Region:
    • Central Africa
    • South Africa
    • North Africa
  • Company Profiles
  • Progenics Pharmaceuticals, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Strategies
    • Recent Developments
  • NorthStar Medical Radioisotopes LLC
  • Curium Pharma
  • Life Molecular Imaging
  • Lantheus Holdings, Inc.
  • Cardinal Health, Inc.
  • General Electric Company
  • Bracco S.p.A.
  • Bayer AG
  • Advanced Accelerator Applications, S.A.
  • Eli Lilly and Company

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Product Type
    • Market Snippet, By Application
    • Market Snippet, By End User
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Regulatory Scenario
  • Reimbursement Scenario
  • PEST Analysis
  • Porter's Analysis
  • Collaborations & Partnerships
  • Mergers & Acquisitions
  • Key Developments
  • Epidemiology

4. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Diagnostic Nuclear Medicine
    • SPECT Radiopharmaceuticals
    • Tc-99m
    • In-111
    • Tl-201
    • Ga-67
    • I-123/I-125/I-131
    • Other SPECT Isotopes
    • PET Radiopharmaceuticals
    • F-18
    • F-18 Florbetapir/Flutemetamol/ Florbetaben
    • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
    • Fluorine-18 Fluciclovine
    • Other F-18 Isotopes
    • Ru-82
    • Other PET Isotopes
  • Therapeutic Nuclear Medicine
    • Ra-223
    • I-131
    • Re-186/Sm-153/Sr-90
    • Lu-177
    • Ir-192
    • Pd-103
    • Cs-131
    • Others

5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Cardiology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Endocrinology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

6. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, 2018-2026
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016-2026, (US$ Mn)

7. Global Radiopharmaceuticals in Nuclear Medicine Market, By Regions, 2016-2026 (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2017 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2026
  • North America
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
  • Middle East
    • Market Size and Forecast, By Product Type, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Application, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By End User, 2016-2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016-2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Progenics Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • NorthStar Medical Radioisotopes LLC
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Curium Pharma
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Life Molecular Imaging
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Lantheus Holdings, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Cardinal Health, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • General Electric Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bracco S.p.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Advanced Accelerator Applications, S.A.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

  • References
  • Research Methodology
  • About us and Sales Contact
Back to Top